LXRX
Lexicon Pharmaceuticals, Inc. NASDAQ Listed Apr 7, 2000$1.68
Mkt Cap $711.8M
52w Low $0.51
81.2% of range
52w High $1.95
50d MA $1.66
200d MA $1.38
P/E (TTM)
-11.6x
EV/EBITDA
-9.2x
P/B
5.5x
Debt/Equity
0.6x
ROE
-46.8%
P/FCF
-6.2x
RSI (14)
—
ATR (14)
—
Beta
0.95
50d MA
$1.66
200d MA
$1.38
Avg Volume
2.7M
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
2445 Technology Forest Boulevard · The Woodlands, TX 77381 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | BMO | — | — | — | 1.60 | +3.1% | +5.0% | — | — | — | — | — |
| Mar 5, 2026 | AMC | -0.07 | -0.04 | +42.9% | 1.64 | +0.0% | +4.3% | -1.8% | -1.2% | +3.6% | +0.0% | — |
| Nov 6, 2025 | AMC | -0.07 | -0.04 | +42.9% | 1.43 | -2.8% | -12.6% | +13.6% | +9.9% | -1.3% | -6.5% | — |
| Aug 6, 2025 | AMC | -0.08 | 0.01 | +112.5% | 1.15 | +2.6% | -2.6% | -3.6% | -3.7% | +1.9% | +4.7% | — |
| May 13, 2025 | AMC | -0.10 | -0.07 | +30.0% | 0.63 | -7.9% | -15.6% | -0.4% | +1.0% | +3.8% | +2.6% | — |
| Mar 6, 2025 | AMC | -0.11 | -0.09 | +18.2% | 0.37 | +6.1% | +6.6% | -9.5% | +1.0% | +6.3% | -6.3% | — |
| Nov 12, 2024 | AMC | -0.17 | -0.18 | -5.9% | 1.19 | -0.8% | -8.4% | -2.8% | -8.0% | -7.2% | -2.7% | — |
| Aug 1, 2024 | AMC | -0.18 | -0.17 | +5.6% | 2.02 | -15.8% | -15.8% | -10.6% | +7.9% | -4.9% | +7.7% | — |
| May 2, 2024 | AMC | -0.18 | -0.20 | -11.1% | 1.70 | -2.4% | +2.4% | +5.2% | -3.3% | +0.0% | +6.8% | — |
| Mar 11, 2024 | AMC | -0.23 | -0.20 | +13.0% | 2.81 | +0.4% | -10.3% | -1.6% | -2.0% | +7.0% | -3.1% | — |
| Nov 8, 2023 | AMC | -0.22 | -0.21 | +4.5% | 1.14 | -0.9% | -9.2% | -2.4% | +5.9% | +4.7% | +1.8% | — |
| Aug 3, 2023 | AMC | -0.17 | -0.22 | -29.4% | 1.92 | -6.2% | -2.6% | -9.1% | +7.1% | -4.9% | -0.6% | — |
| May 2, 2023 | AMC | -0.17 | -0.17 | +0.0% | 2.38 | +4.6% | +15.1% | +12.4% | +13.3% | -6.6% | -7.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.56 | $1.56 | +0.0% | +5.1% | +4.9% | -2.3% | -3.0% | +1.2% |
| Mar 10 | Citigroup | Maintains | Buy → Buy | — | $1.68 | $1.72 | +2.4% | -1.2% | +3.6% | +0.0% | -1.7% | -4.7% |
| Mar 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.63 | $1.54 | -5.5% | +0.6% | +4.3% | -1.8% | -1.2% | +3.6% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.10 | $1.12 | +1.8% | +1.8% | -3.6% | -0.9% | +1.9% | -0.9% |
| Aug 7 | Citigroup | Maintains | Buy → Buy | — | $1.15 | $1.18 | +2.6% | -2.6% | -3.6% | -3.7% | +1.9% | +4.7% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.73 | $0.75 | +1.9% | +4.9% | +16.6% | +3.4% | -11.7% | +15.2% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.35 | $0.65 | +88.4% | +64.1% | -19.2% | +0.7% | +8.4% | -11.9% |
| Mar 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $0.37 | $0.39 | +6.1% | +6.6% | -9.5% | +1.0% | +6.3% | -6.3% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.37 | $0.39 | +6.1% | +6.6% | -9.5% | +1.0% | +6.3% | -6.3% |
| Mar 7 | Needham | Maintains | Hold → Hold | — | $0.37 | $0.39 | +6.1% | +6.6% | -9.5% | +1.0% | +6.3% | -6.3% |
| Mar 4 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $0.29 | $0.31 | +4.6% | +11.0% | +3.4% | +9.4% | +6.6% | -9.5% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.70 | $0.37 | -46.4% | -58.2% | +11.0% | +3.4% | +9.4% | +6.6% |
| Mar 3 | Needham | Maintains | Hold → Hold | — | $0.70 | $0.37 | -46.4% | -58.2% | +11.0% | +3.4% | +9.4% | +6.6% |
| Jan 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.93 | $0.94 | +0.7% | -11.3% | -0.7% | -7.7% | -3.8% | +4.5% |
| Jan 29 | Needham | Maintains | Hold → Hold | — | $0.93 | $0.94 | +0.7% | -11.3% | -0.7% | -7.7% | -3.8% | +4.5% |
| Dec 23 | Needham | Maintains | Hold → Hold | — | $0.71 | $0.67 | -5.8% | +15.7% | -8.4% | +3.6% | -1.5% | -7.0% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.19 | $1.18 | -0.8% | -8.4% | -2.8% | -8.0% | -7.2% | -2.7% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.21 | $1.20 | -0.8% | -1.7% | +1.7% | +7.4% | -2.3% | +0.0% |
| Nov 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $1.20 | -38.5% | -37.4% | -0.8% | -1.7% | +1.7% | +7.4% |
| Oct 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.03 | $2.01 | -1.0% | -3.9% | +0.0% | -37.4% | -0.8% | -1.7% |
| Oct 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.94 | $1.96 | +1.0% | -4.1% | -1.1% | -2.2% | +3.3% | +9.1% |
| Oct 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.91 | $1.93 | +1.0% | +5.2% | +3.5% | -6.2% | -0.5% | -4.1% |
| Oct 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.61 | $1.60 | -0.6% | +0.0% | +5.0% | -0.6% | +0.0% | -3.0% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.56 | +1.3% | +3.9% | -1.9% | +0.6% | +1.9% | +0.0% |
| Sep 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.68 | +0.6% | +1.2% | -1.2% | +1.8% | -4.1% | -0.6% |
| Sep 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.73 | $1.72 | -0.6% | -6.9% | +1.2% | -0.6% | -0.6% | +3.7% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.68 | $1.69 | +0.6% | +13.7% | -4.2% | +0.0% | -3.3% | -2.8% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.59 | $1.60 | +0.6% | +8.8% | -5.2% | +0.0% | +1.2% | +1.8% |
| Aug 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.02 | $1.70 | -15.8% | -15.8% | -10.6% | +7.9% | -4.9% | +7.7% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.12 | $2.13 | +0.5% | +5.2% | -4.5% | -1.9% | -4.8% | +6.0% |
| Jun 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.85 | +0.0% | -2.2% | -6.1% | -1.2% | +3.6% | -3.4% |
| May 31 | Citigroup | Maintains | Buy → Buy | — | $2.90 | $2.91 | +0.3% | +13.8% | -17.9% | +1.5% | -7.6% | +4.7% |
| May 30 | Needham | Maintains | Hold → Hold | — | $3.18 | $3.40 | +6.9% | -8.8% | +13.8% | -17.9% | +1.5% | -7.6% |
| Mar 7 | Jefferies | Maintains | Hold → Hold | — | $2.60 | $2.57 | -1.2% | -0.8% | -5.4% | -7.4% | -2.2% | +4.5% |
| Nov 22 | Citigroup | Maintains | Buy → Buy | — | $2.19 | $2.22 | +1.4% | +1.4% | -4.1% | +0.0% | -5.2% | +1.5% |
| Aug 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $2.76 | $2.90 | +5.1% | +14.9% | +8.2% | -4.4% | -6.7% | +1.3% |
| Jul 1 | Citigroup | Maintains | Buy → Buy | — | $1.86 | $1.92 | +3.2% | +4.3% | +41.8% | -4.4% | +6.8% | +2.1% |
| Jan 29 | Wedbush | Downgrade | Outperform → Neutral | — | $8.06 | $8.02 | -0.5% | -1.9% | +4.6% | +9.9% | -5.2% | -1.5% |
| Jan 29 | JP Morgan | Upgrade | Underweight → Neutral | — | $8.06 | $8.02 | -0.5% | -1.9% | +4.6% | +9.9% | -5.2% | -1.5% |
| Dec 8 | Citigroup | Upgrade | Neutral → Buy | — | $1.73 | $2.35 | +35.8% | +78.0% | -5.8% | +14.5% | -6.0% | -4.5% |
| Nov 18 | Gabelli & Co. | Upgrade | Hold → Buy | — | $1.81 | $1.81 | +0.0% | -11.6% | -3.1% | -3.2% | -2.7% | +8.2% |
| Apr 28 | Citigroup | Maintains | Neutral → Neutral | — | $2.30 | $2.33 | +1.3% | -7.8% | +0.0% | -10.8% | +0.5% | -0.5% |
| Dec 11 | Gabelli & Co. | Downgrade | Buy → Hold | — | $5.15 | $5.01 | -2.7% | -1.9% | +0.4% | -4.1% | -0.2% | -5.2% |
| Nov 8 | Citigroup | Downgrade | Buy → Neutral | — | $3.88 | $3.76 | -3.1% | -9.3% | +0.9% | -1.1% | -1.1% | -1.4% |
| Sep 11 | Gabelli & Co. | Upgrade | Hold → Buy | — | $1.72 | $2.36 | +37.2% | +27.9% | +10.0% | -3.3% | +17.1% | +7.3% |
| Jul 30 | Citigroup | Maintains | Buy → Buy | — | $1.69 | $1.70 | +0.6% | -1.8% | -18.7% | -3.0% | -8.4% | +10.8% |
| Jul 29 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $5.69 | $2.47 | -56.6% | -70.3% | -1.8% | -18.7% | -3.0% | -8.4% |
| Jul 29 | Stifel | Downgrade | Buy → Hold | — | $5.69 | $2.47 | -56.6% | -70.3% | -1.8% | -18.7% | -3.0% | -8.4% |
| Mar 25 | Gabelli & Co. | Upgrade | Sell → Hold | — | $6.20 | $5.95 | -4.0% | -8.7% | -4.4% | -1.7% | -1.1% | +5.7% |
| Mar 14 | Gabelli & Co. | Downgrade | Hold → Sell | — | $7.86 | $7.34 | -6.6% | -6.7% | +1.1% | +2.8% | +2.4% | -0.8% |
No insider trades available.
8-K · 2.02
!! High
Lexicon Pharmaceuticals, Inc. -- 8-K 2.02: Earnings Results
Lexicon Pharmaceuticals reported Q1 2026 financial results on May 7, 2026, with detailed earnings information available in the attached press release exhibit.
May 7
8-K
Lexicon Pharmaceuticals, Inc. -- 8-K Filing
Lexicon Pharmaceuticals received FDA clearance for pilavapadin Phase 3 development and secured over $100 million in cash from a capital raise and Novo Nordisk milestone payment, strengthening its financial position.
Mar 5
8-K · 1.01
! Medium
Lexicon Pharmaceuticals, Inc. -- 8-K 1.01: Equity Issuance
Lexicon Pharmaceuticals raised $41.6 million through a public equity offering underwritten by Jefferies LLC, providing capital for drug development and operations.
Feb 2
Data updated apr 25, 2026 8:14pm
· Source: massive.com